rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    HALO
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Halozyme Therapeutics director Matthew Posard sells $482,146 in stock
      3h agoInvesting.comHALO
      Halozyme’s president and CEO Helen Torley sells $6.0m in stock
      Nov 17Investing.comHALO
      Halozyme Therapeutics (HALO) Stock Gets Fair Value Boost After Q3 Analyst Revisions
      Nov 12Yahoo FinanceHALO
      Halozyme Therapeutics (HALO) Stock Looks In Line As ENHANZE Approval Lands
      Nov 12Yahoo FinanceHALO
      Can You Make Money Off Halozyme Stock Now?
      Nov 11Yahoo FinanceHALO
      Halozyme stock downgraded at Morgan Stanley (HALO:NASDAQ)

      Halozyme Therapeutics (HALO) stock slips as Morgan Stanley downgrades the company, citing valuation concerns following its recent Q3 2026 results. Read more here.

      Nov 11Seeking AlphaHALOMS
      Will HALO's Partner Royalties Drive Growth for the Rest of 2026?
      Nov 11Yahoo FinanceHALO
      Morgan Stanley downgrades Halozyme stock rating on valuation
      Nov 11Investing.comHALO
      Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why
      Nov 10Yahoo FinanceHALO
      Are Medical Stocks Lagging Halozyme Therapeutics (HALO) This Year?
      Nov 10Yahoo FinanceHALO
      5 Stock Picks Last Week From Wall Street's Most Accurate Analysts
      Nov 9BenzingaHALO
      Halozyme Stocks Slip 4.28% Despite 39% Revenue Growth and Modestly Higher Guidance
      Nov 6Yahoo FinanceHALO
      Halozyme dips as Leerink downgrades on “marginal” Q3 upside
      Nov 6Seeking AlphaHALO
      Halozyme Reaffirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Medicare Drug Price Negotiation Program Final Rule for IPAY 2029
      Nov 6Yahoo FinanceHALO
      HALO Q3 Earnings Call Highlights Royalty Growth and Patent Dispute
      Nov 6Yahoo FinanceHALO
      Halozyme Stock Jumps On Strong Earnings But Guidance Reset Raises Questions
      Nov 6Yahoo FinanceHALO
      Why is Halozyme Therapeutics stock sliding today?
      Nov 6Investing.comHALO
      Halozyme (HALO) Q3 2026 Earnings Call Transcript
      Nov 6The Globe and MailHALO
      What Halozyme Therapeutics (HALO) Said on Its Q3 Earnings Call
      Nov 6Yahoo FinanceHALO
      Halozyme Therapeutics Inc (HALO) (Q3 2026) Earnings Call Highlights: Record Revenue, Raised ...

      Halozyme Therapeutics Inc (HALO) posted 39% revenue growth with record royalties, lifted its full-year 2026 outlook, and scored a Dutch patent victory against Merck even as US litigation drags on.

      Nov 6Yahoo FinanceHALO
      Halozyme falls 6% as raised guidance fails to impress investors
      Nov 5Yahoo FinanceHALO
      Halozyme falls 6% as raised guidance fails to impress investors By Investing.com
      Nov 5Investing.comHALO
      Halozyme Therapeutics Q3 2026 Earnings Call Transcript
      Nov 5BenzingaHALO
      Halozyme Therapeutics (HALO) Tops Q3 Earnings and Revenue Estimates
      Nov 5Yahoo FinanceHALO
      Halozyme Therapeutics (NASDAQ:HALO) surprises with Q3 2026 sales but stock drops
      Nov 5Yahoo FinanceHALO
      Halozyme Therapeutics (HALO) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
      Nov 4Yahoo FinanceHALO
      HALO Gears Up to Report Q3 Earnings: Is a Beat in the Cards?
      Oct 30Yahoo FinanceHALO
      Halozyme Therapeutics (HALO) Reports Next Week: Wall Street Expects Earnings Growth
      Oct 29Yahoo FinanceHALO
      What Did Halozyme Stock Investors Miss Before The Run?
      Oct 28Yahoo FinanceHALO
      Strong Royalties and New Launches Accelerate Halozyme Therapeutics’ (HALO) Growth Momentum
      Oct 27Yahoo FinanceHALO
      Halozyme Therapeutics stock hits all-time high at 125.53 USD
      Oct 23Investing.comHALO
      How Halozyme Is Rivaling Merck And Hitting New Highs

      Halozyme's tech allow IV drugs to be given instead with shots.

      Oct 23Investor's Business DailyHALOMRK
      Halozyme to Report Third Quarter 2026 Financial and Operating Results
      Oct 22Yahoo FinanceHALO
      The Zacks Analyst Blog Highlights Chord Energy, Halozyme, Sezzle, SanDisk and Teradyne
      Oct 22Yahoo FinanceCHRDHALOSEZLSNDKTER
      The Zacks Analyst Blog Highlights Ross Stores, Roku, APA, Corcept Therapeutics and Halozyme Therapeutics

      Detailed price information for Apa Corp (APA-Q) from The Globe and Mail including charting and trades.

      Oct 19The Globe and MailAPACORTHALO
      Zacks.com featured highlights include Halozyme Therapeutics, GigaCloud Technology, Lindblad Expeditions, Permian Resources and Chevron

      Halozyme Therapeutics, GigaCloud Technology, Lindblad Expeditions, Permian Resources and Chevron stand out for strong share gains and rising earnings estimates under a relative price strength strategy.

      Oct 19Yahoo FinanceGCTHALOLIND
      H.C. Wainwright reiterates Halozyme stock rating on Takeda trial data
      Oct 16Investing.comHALOTAK
      Is Expanded Argenx Deal Altering The Investment Case For Halozyme Therapeutics (HALO)?
      Oct 16Yahoo FinanceHALO
      Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today
      Oct 15Yahoo FinanceHALO
      Halozyme Therapeutics stock hits all-time high at 116.85 USD
      Oct 14Investing.comHALO
      Here's How Much $100 Invested In Halozyme Therapeutics 5 Years Ago Would Be Worth Today - Halozyme Therap

      Halozyme Therapeutics (NASDAQ:HALO) has outperformed the market over the past 5 years by 12.8% on an annualized basis producing an average annual return of 24.48%. Currently, Halozyme Therapeutics has a market

      Oct 13BenzingaHALO
      Will Halozyme Therapeutics (HALO) Beat Estimates Again in Its Next Earnings Report?
      Oct 13Yahoo FinanceHALO
      H.C. Wainwright reiterates Halozyme stock rating on FDA approval
      Oct 13Investing.comHALO
      Halozyme director Matthew Posard sells $567,660 of common stock
      Oct 13Investing.comHALO
      Analysts Conflicted on These Healthcare Names: Sanofi (OtherSNYNF), Arvinas Holding Company (ARVN) and Halozyme (HALO)

      Detailed price information for Arvinas Inc (ARVN-Q) from The Globe and Mail including charting and trades.

      Oct 9The Globe and MailARVNHALO
      Halozyme CEO Helen Torley sells $6.61m in shares
      Oct 9Investing.comHALO
      HALO Wins Court Order Blocking Merck's Keytruda SC in Europe
      Oct 8Yahoo FinanceHALOMRK
      Argenx stock falls on late-stage trial setback (ARGX:NASDAQ)

      Argenx (ARGX) stock drops as the firm ends a late-stage trial for an injectable version of its blockbuster therapy, Vyvgart targeting Sjögren's disease. Read more here.

      Oct 8Seeking AlphaARGXHALO
      Halozyme Therapeutics (HALO) Expands Argenx Deal, Is It Still 27% Below Fair Value?
      Oct 8Yahoo FinanceARGXHALO
      Is Halozyme’s EU Injunction on Subcutaneous Keytruda Reshaping the Investment Case For Merck (MRK)?
      Oct 7Yahoo FinanceHALOMRK

      This is the newest page. Registered accounts read further back.